Thrombin-Jmi, Thrombocoll Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The thrombin-jmi, thrombocoll market research report is one of a series of new reports that provides thrombin-jmi, thrombocoll market statistics, including the thrombin-jmi, thrombocoll industry global market size, regional shares, competitors with the thrombin-jmi, thrombocoll market share, detailed thrombin-jmi, thrombocoll market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombin-jmi, thrombocoll industry. This thrombin-jmi, thrombocoll market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to growing adoption of minimally invasive surgeries, rising demand for recombinant thrombin, rising prevalence of cardiovascular, expanding healthcare access in emerging markets, and increased need for hemostatic drugs. Major trends in the forecast period include advancements in hemostatic agent technologies, minimally invasive surgical techniques, advancements in recombinant technology, innovations in drug delivery systems, and advancements in hemostatic biomaterials.

The growing incidence of bleeding disorders is expected to drive the growth of the Thrombin-JMI and Thrombocoll market in the coming years. Bleeding disorders refer to conditions where the blood does not clot properly, leading to excessive or abnormal blood loss, either internally or externally, due to injuries or medical conditions. Factors such as an aging population and increased use of anticoagulants are contributing to a higher risk of bleeding complications. Thrombin-JMI and Thrombocoll are vital in managing these bleeding issues by promoting clot formation. Thrombin-JMI activates the clotting cascade, while Thrombocoll enhances platelet aggregation and fibrin formation at the wound site. For example, in October 2023, the World Federation of Hemophilia reported that in 2022, approximately 427,685 individuals worldwide were diagnosed with bleeding disorders. This includes 257,146 cases of hemophilia, which further illustrates the growing prevalence of bleeding conditions, fueling the demand for products such as Thrombin-JMI and Thrombocoll.

The rising number of surgical procedures is another factor expected to propel the growth of the Thrombin-JMI and Thrombocoll market. Surgical procedures, which involve medical operations to treat diseases or injuries, often require interventions such as incisions or other invasive methods. The increase in surgeries can be attributed to an aging population in need of medical care, as well as advancements in minimally invasive techniques that offer safer outcomes and quicker recovery times. Thrombin-JMI and Thrombocoll are commonly used in these surgeries to control bleeding. Thrombin-JMI activates fibrinogen to assist in clot formation, while Thrombocoll provides a collagen scaffold to stimulate platelet aggregation. According to the International Society of Aesthetic Plastic Surgery, in 2022, plastic surgeons performed 11.2% more procedures compared to the previous year, totaling over 14.9 million surgical and 18.8 million non-surgical procedures globally. This surge in surgical interventions directly contributes to the growing demand for hemostatic agents such as Thrombin-JMI and Thrombocoll.

The expanding aging population is also expected to drive the growth of the Thrombin-JMI and Thrombocoll market. As life expectancy increases and birth rates decline, the proportion of elderly individuals in the population is steadily growing. Advances in healthcare have contributed to longer life spans, resulting in a higher proportion of elderly people who are more prone to slower wound healing and increased bleeding risks due to age-related conditions. Thrombin-JMI and Thrombocoll play a crucial role in managing these challenges by promoting clotting and controlling bleeding. For instance, according to the U.S. Census Bureau, the number of people aged 65 and older in the U.S. is expected to grow by 47%, from 58 million in 2022 to 82 million by 2050. As this demographic grows, the need for products that help manage bleeding complications in older adults will increase, thereby driving market growth for Thrombin-JMI and Thrombocoll.

The key company operating in the thrombin-jmi, thrombocoll market is Pfizer Inc.

North America was the largest region in the thrombin-jmi, thrombocoll market in 2024. The regions covered in thrombin-jmi, thrombocoll report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the thrombin-jmi, thrombocoll market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Thrombin-JMI and Thrombocoll are medical products designed to manage bleeding during surgical procedures. Thrombin-JMI is a human thrombin-based hemostatic agent that helps control bleeding by promoting clot formation during surgery. Thrombocoll, a collagen-based hemostatic product, aids in stopping bleeding by facilitating platelet aggregation and clot formation during surgeries or invasive procedures. Both products are commonly used in clinical settings to prevent or manage excessive bleeding during surgeries.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Thrombin-JMI and Thrombocoll include surgical procedures and trauma management. Surgical procedures refer to medical operations performed by skilled surgeons to treat or manage diseases, injuries, or conditions, often involving incisions or modifications to the body. These products are available in both solution and powder formulations, and are used by various end users, including hospitals, diagnostic centers, and clinics.

The thrombin-jmi, thrombocoll market consists of sales of hemostatic kits, reconstitution kits, coseal, floseal hemostatic matrix, and tachoSil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.